Dulabh Monga
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Office (412) 325-5700
Fax (412) 442-2570
314 East North Avenue,
Pittsburgh, PA 15212
About
Dulabh Monga
Dulabh K. Monga, MD, is a medical oncologist who specializes in treating gastrointestinal and hepatobiliary malignancies. She is an associate professor of medicine at Drexel University School of Medicine.
Primary Specialty
Oncologist
Practice
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Gender
Female
Education
Punjab University Dayanand Medical College and Hospital
Training
Allegheny General Hospital, UPMC Bedford Memorial
Certification
American Board of Internal Medicine-Medical Oncology
Accepting New Patients
Degrees
Medical Doctor
Admitting Hospitals
Allegheny General Hospital, Allegheny Valley Hospital, Saint Vincent Hospital, West Penn Hospital, Forbes Hospital
Office Name
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Languages
Punjabi, Hindi, English
Business Hours
Monday:10:00 AM - 4:00 PM
Tuesday:10:00 AM - 4:00 PM
Wednesday:10:00 AM - 4:00 PM
Thursday:10:00 AM - 4:00 PM
Friday:10:00 AM - 4:00 PM
Saturday:Closed
Sunday:Closed
Services
clear cell renal cancer, chemotherapy iv infusion, multi-cancer early detection blood test, relapsed myeloma, testicular tumor, adjuvant chemotherapy, solid tumors, advanced malignancies, systemic therapy, mediastinal lymphadenopathy, gleason score, intravesical chemotherapy, hereditary kidney cancer, hormone receptor negative breast cancer, colorectal metastases, ductal carcinoma in situ (dcis), lobular carcinoma in situ (lcis), personal history of cancer, intestinal cancer, secondary cancer screening, long term side effects of cancer treatment, personal history of radiation therapy, personal history of chemotherapy, blood cancer chemotherapy, hyperthermic intraperitoneal chemotherapy (hipec), gynecologic cancer, blood transfusion therapy, prostate cancer chemotherapy, bladder cancer chemotherapy, testicular cancer chemotherapy, non steroidal aromatase inhibitors, hormone based chemotherapy, adolescent and young adult cancer (aya), metastatic rib cancer, breast cancer immunotherapy, relapsed hodgkin lymphoma, lymphoproliferative disorder, intravesical therapy, hormone receptor positive breast cancer, her2 positive breast cancer, carcinoma of unknown primary, targeted molecular therapy, cancer related anxiety disorder, cancer related depression, cancer related bereavement disorder, cancer related stress disorder, intrathecal chemotherapy, maintenance chemotherapy, consolidation chemotherapy, induction chemotherapy, er negative breast cancer, urachal tumor, malignant brain neoplasm, clinical trials, squamous cell carcinoma of the head and neck, aids related malignancies, intraarterial chemotherapy of tumors, cervical and endometrial cancers, genitourinary cancers, inflammatory breast cancer, recurrent breast cancer, occupational cancer, brain metastases, ear and temporal bone cancer, liver metastases, malignant carcinoid tumor of colon, ear canal cancer, hodgkin lymphoma, triple negative breast cancer, breast cancer therapy, breast cancer counseling, cancer immunotherapy, prostate cancer, adenocarcinoma of lung, acute lymphoblastic leukemia (all), abdominal chemotherapy, abdominal cancer, breast cancer, papillary cancer of thyroid, medullary cancer of thyroid, follicular cancer of thyroid, parotid cancer, squamous cancer of the lung, esophageal cancer, tracheal cancer, oral complications of cancer, non hodgkin lymphoma, myeloproliferative diseases, lymphedema therapy, hematologic malignancies, head and neck cancer, cancer related fatigue, hereditary cancer risk, ovarian cancer, head and neck tumors, reduced intensity conditioning regimens, bladder cancer, thyroid cancer, stomach cancer